^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    busulfan

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    3d
    MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P3, N=700, Active, not recruiting, University of Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • cyclophosphamide • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone • fludarabine IV • busulfan
    6d
    Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov)
    P2, N=153, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • daretabart (hu1418K322A)
    9d
    Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers (clinicaltrials.gov)
    P2, N=98, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    RUNX1 (RUNX Family Transcription Factor 1)
    |
    RUNX1 mutation
    |
    cyclophosphamide • fludarabine IV • busulfan
    12d
    Augmented myeloablative conditioning with olaparib in allogeneic hematopoietic stem cell transplantation for relapsed/refractory RUNX1::RUNX1T1-positive acute myeloid leukemia. (PubMed, Front Oncol)
    The conditioning regimen included olaparib, FLAG, busulfan, and cyclophosphamide. These findings highlight the potential of PARPi-enhanced conditioning to overcome chemotherapy resistance and reduce relapse by targeting leukemia stem cells (LSCs) through immune-mediated mechanisms. Small-sample retrospective studies have inherent limitations; hence further prospective studies are warranted to validate these results.
    Journal
    |
    HRD (Homologous Recombination Deficiency) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
    |
    RUNX1-RUNX1T1 fusion
    |
    Lynparza (olaparib) • cyclophosphamide • busulfan
    13d
    A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies (clinicaltrials.gov)
    P3, N=232, Active, not recruiting, First Affiliated Hospital of Zhejiang University | Recruiting --> Active, not recruiting | N=176 --> 232 | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Sep 2025 --> Apr 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    cytarabine • cyclophosphamide • busulfan • cyclosporin A microemulsion
    13d
    Clinical application of base editing for treating β-thalassaemia. (PubMed, Nature)
    The adverse events of CS-101 were generally consistent with those of busulfan myeloablative conditioning and autologous haematopoietic stem and progenitor cell transplantation. No deaths or cancer occurrences were reported. In summary, CS-101 can lead to rapid and sustained increases in both total haemoglobin and HbF levels, which resulted in early and enduring transfusion independence.
    Journal
    |
    CD34 (CD34 molecule)
    |
    busulfan
    23d
    A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, The First Affiliated Hospital of Soochow University
    New trial
    |
    TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1)
    |
    TP53 mutation • SF3B1 mutation • Chr del(5q)
    |
    cytarabine • azacitidine • cladribine • melphalan • busulfan
    23d
    P30CA015704: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=61, Completed, Fred Hutchinson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    24d
    OTL-103-4: A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome (clinicaltrials.gov)
    P3, N=10, Recruiting, Fondazione Telethon | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • fludarabine IV • busulfan • Granocyte (lenograstim) • plerixafor
    27d
    In silico and in vitro investigations of the drug-drug interaction mechanisms between fludarabine and busulfan. (PubMed, Front Pharmacol)
    The present study underscores the importance of empirically validating in silico observations in pharmacological research by emphasizing the minimal effect of Flu on GST activity and its implications in clinical oncology. Moreover, the findings suggest that Flu is not likely to alter BU pharmacokinetics via the GSH-conjugation pathway.
    Preclinical • Journal
    |
    GSTP1 (Glutathione S-transferase pi 1) • GSTM1 (Glutathione S-transferase mu 1)
    |
    fludarabine IV • busulfan
    29d
    US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (clinicaltrials.gov)
    P1/2, N=13, Completed, ExCellThera inc. | Recruiting --> Completed | Trial completion date: Jun 2027 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)
    |
    cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • Zemcelpro (dorocubicel)
    1m
    ACCESS: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (clinicaltrials.gov)
    P2, N=300, Active, not recruiting, Center for International Blood and Marrow Transplant Research | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan